公开(公告)号：WO2014164913A1

公开(公告)日：2014-10-09

申请号：PCT/US2014/023784

申请日：2014-03-11

Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： KOPECEK, Jindrich, Henry ,  YANG, Jiyuan ,  CHU, Te-Wei

IPC: A61K39/00 ,  A61K39/395

CPC classification number: A61K31/712 ,  A61K47/48176 ,  A61K47/48746 ,  A61K47/58 ,  A61K47/6807 ,  A61K47/6849 ,  A61K47/6897 ,  A61K2039/505 ,  C07K16/2887 ,  C07K2317/35 ,  C07K2317/40 ,  C07K2317/55 ,  C07K2317/73

Abstract: In an aspect, the invention relates to compositions, methods, and kits for inducing apoptosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract translation: 一方面，本发明涉及用于诱导凋亡的组合物，方法和试剂盒。 该摘要旨在作为用于在特定技术中进行搜索的扫描工具，而不意在限制本发明。

公开(公告)号：WO2012156920A1

公开(公告)日：2012-11-22

申请号：PCT/IB2012/052447

申请日：2012-05-16

Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V. ,  ROBILLARD, Marc, Stefan ,  TEN HOEVE, Wolter ,  VERSTEEGEN, Ronny, Mathieu ,  ROSSIN, Raffaella ,  HOEBEN, Freek, Johannes, Maria

Inventor： ROBILLARD, Marc, Stefan ,  TEN HOEVE, Wolter ,  VERSTEEGEN, Ronny, Mathieu ,  ROSSIN, Raffaella ,  HOEBEN, Freek, Johannes, Maria

IPC: A61K47/48

CPC classification number: A61K47/6803 ,  A61K31/435 ,  A61K31/444 ,  A61K31/704 ,  A61K38/05 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/22 ,  A61K47/545 ,  A61K47/555 ,  A61K47/558 ,  A61K47/6897 ,  B82Y5/00 ,  C07C33/16 ,  C07D237/26 ,  C07D257/08 ,  Y02A50/471

Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.

Abstract translation: 本发明涉及用于治疗的前药活化方法，其中使用由彼此表现出生物正交反应性的非生物反应性化学基团组成。 本发明还涉及包含至少一种前药和至少一种活化剂的前药药盒，其中前药包含药物和第一生物正交反应性基团（触发剂），并且其中活化剂包含第二生物正交反应性基团 。 本发明还涉及在上述方法和试剂盒中使用的靶向治疗剂。 本发明特别涉及抗体 - 药物偶联物和双和三特异性抗体衍生物。

公开(公告)号：WO2012085789A1

公开(公告)日：2012-06-28

申请号：PCT/IB2011/055730

申请日：2011-12-16

Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V. ,  ROSSIN, Raffaella ,  LAEPPCHEN, Tilman ,  VAN DEN BOSCH, Sandra Martina ,  ROBILLARD, Marc Stefan ,  VERSTEEGEN, Ronny Mathieu

Inventor： ROSSIN, Raffaella ,  LAEPPCHEN, Tilman ,  VAN DEN BOSCH, Sandra Martina ,  ROBILLARD, Marc Stefan ,  VERSTEEGEN, Ronny Mathieu

IPC: A61K47/48 ,  A61K49/08 ,  A61K51/10 ,  A61K51/04 ,  A61P35/00

CPC classification number: A61K51/044 ,  A61K31/495 ,  A61K45/06 ,  A61K47/4873 ,  A61K47/48746 ,  A61K47/6893 ,  A61K47/6897 ,  A61K51/0495 ,  A61K51/1027 ,  A61K51/1045 ,  A61K51/1093 ,  B82Y5/00

Abstract: Described is a method, and a combination of agents for used therein, by which an agent administered to a subject can be rapidly cleared from circulation. This is achieved by providing an Administration Agent (e.g. a probe for pretargeting) with a reactive group and providing a Clearing Agent with another reactive group, said reactive groups forming a bio-orthogonally reactive pair. Preferably, the reactive pair comprises a cyclooctene or cyclooctyn as one reactant, and a diene as the other reactant. The method and combination can be used for the removal of any bindable molecule from circulation, such as an excess of a pre-targeting probe in the course of a pre-targeting method, a targeting or imaging agent delivered, or the removal of any biomolecule already present in circulation.

Abstract translation: 描述了一种方法，以及其中使用的试剂的组合，通过其可以将施用于受试者的药剂迅速地从循环中清除。 这通过提供与反应性基团的给药剂（例如用于预靶向的探针）并向澄清剂提供另一反应性基团来实现，所述反应性基团形成生物正交反应性对。 优选地，反应性对包括作为一种反应物的环辛烯或环辛烯，和作为其它反应物的二烯。 该方法和组合可用于从循环中除去任何可结合的分子，例如在预靶向法，靶向或成像剂递送过程中过量的预靶向探针，或去除任何生物分子 已经流通。

公开(公告)号：WO2012082841A2

公开(公告)日：2012-06-21

申请号：PCT/US2011/064808

申请日：2011-12-14

Applicant: UNIVERSITY OF MARYLAND, BALTIMORE ,  DAVILA, Eduardo ,  TAMADA, Koji

Inventor： DAVILA, Eduardo ,  TAMADA, Koji

IPC: A61K39/395 ,  A61K31/4188 ,  A61P35/00

CPC classification number: A61K39/39558 ,  A61K35/17 ,  A61K47/4813 ,  A61K47/48584 ,  A61K47/486 ,  A61K47/48615 ,  A61K47/48746 ,  A61K47/555 ,  A61K47/6855 ,  A61K47/6859 ,  A61K47/6863 ,  A61K47/6897 ,  A61K2039/5156 ,  A61K2039/572 ,  A61K2039/585 ,  C07K16/2863 ,  C07K16/44 ,  C07K2317/622 ,  C07K2319/00 ,  C12N5/0636 ,  C12N2501/515 ,  C12N2510/00

Abstract: The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, FITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of FITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.

Abstract translation: 本发明提供了一种通用但适应性强的抗标签嵌合抗原受体（AT-CAR）系统，其提供T细胞识别和杀死标记有标记抗体的靶细胞如肿瘤细胞的能力和特异性 。 作为示例，已经开发出表达FITC-CAR的T细胞，当这些细胞被癌反应性FITC标记的抗体结合时，T细胞特异性识别各种人类癌细胞。 显示表达FITC-CAR的T细胞的活化诱导有效的靶分解，T细胞增殖和细胞因子/趋化因子产生。 该系统可用于治疗患有癌症的受试者。

公开(公告)号：WO2011072124A1

公开(公告)日：2011-06-16

申请号：PCT/US2010/059686

申请日：2010-12-09

Applicant: IMMUNOMEDICS, INC. ,  MCBRIDE, William J. ,  D'SOUZA, Christopher A. ,  CHANG, Chien-Hsing ,  GOLDENBERG, David M.

Inventor： MCBRIDE, William J. ,  D'SOUZA, Christopher A. ,  CHANG, Chien-Hsing ,  GOLDENBERG, David M.

IPC: A61K39/395

CPC classification number: C07K16/303 ,  A61K47/6879 ,  A61K47/6897 ,  B82Y5/00 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/31 ,  C07K2317/626 ,  C07K2317/73

Abstract: The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties.

Abstract translation: 本发明涉及治疗剂预靶向递送的方法和组合物。 在优选的实施方案中，预靶向方法包括：a）将双特异性抗体施用于疾病相关抗原的第一结合位点和可靶向构建体上的半抗原; b）施用包含至少一种治疗剂的可靶向构建体。 在优选的实施方案中，双特异性抗体通过对接和锁定（DNL）技术制备。 在更优选的实施方案中，可靶向构建体包含一个或多个SN-38部分。

公开(公告)号：WO2007098575A1

公开(公告)日：2007-09-07

申请号：PCT/CA2007/000281

申请日：2007-02-23

Applicant: ARIUS RESEARCH, INC.

Inventor： YOUNG, David, S., F. ,  FINDLAY, Helen, P. ,  HAHN, Susan, E. ,  CECHETTO, Lisa, M. ,  MCCONKEY, Fortunata

IPC: C07K16/30 ,  A61K38/00 ,  A61K39/395 ,  A61K47/48 ,  A61K51/08 ,  A61P35/00 ,  A61P37/04 ,  C07K16/28 ,  C12P21/08 ,  G01N33/574 ,  G01N33/577 ,  C07K14/705

CPC classification number: C07K16/2884 ,  A61K47/6849 ,  A61K47/6897 ,  A61K49/0013 ,  A61K49/0058 ,  A61K2039/505 ,  B82Y5/00 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/73 ,  G01N33/5082 ,  G01N33/574 ,  G01N33/57492 ,  G01N2333/70585

Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumour cells evidencing surface expression of CD44; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

Abstract translation: 本发明涉及癌症疾病的诊断和治疗，特别涉及证明CD44表面表达的肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用任选与一种或多种化学治疗剂组合的癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。

公开(公告)号：WO2005067980A3

公开(公告)日：2006-10-26

申请号：PCT/US2005000816

申请日：2005-01-10

Applicant: POINTILLISTE INC ,  AULT-RICHE DANA ,  LEVY RONALD

Inventor： AULT-RICHE DANA ,  LEVY RONALD

IPC: A61K39/395 ,  A61K47/48 ,  C07K16/28 ,  C07K16/42

CPC classification number: B82Y5/00 ,  A61K39/39566 ,  A61K47/665 ,  A61K47/6897 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/4241 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2319/30 ,  A61K2300/00

Abstract: Therapeutic complexes and components of therapeutic complexes are provided herein. Also provided are methods of preparing therapeutic complexes and methods of administering therapeutic complexes.

Abstract translation: 本文提供治疗复合物和治疗复合物的组分。 还提供了制备治疗复合物的方法和施用治疗复合物的方法。

公开(公告)号：WO2005025518A3

公开(公告)日：2005-10-06

申请号：PCT/US2004029970

申请日：2004-09-13

Applicant: UAB RESEARCH FOUNDATION ,  BENOS DALE J ,  BUBIEN JAMES K ,  GILLESPIE G YANCEY

Inventor： BENOS DALE J ,  BUBIEN JAMES K ,  GILLESPIE G YANCEY

IPC: A01N37/18 ,  A01N61/00 ,  A61K20060101 ,  A61K39/00 ,  A61K39/385 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  C12Q1/00

CPC classification number: A61K39/0011 ,  A61K31/00 ,  A61K38/164 ,  A61K38/168 ,  A61K38/17 ,  A61K47/62 ,  A61K47/6897 ,  A61K51/10 ,  A61K2039/6031 ,  B82Y5/00 ,  A61K2300/00

Abstract: Described is a constitutive inward Na currents found in a variety of human cancers. The constitutive inward Na current plays a role in increased cellular proliferation, cellular migration and volume regulation. The inward current is mediated, at least in part, by AISC-­ containing Na channels. In addition, an inhibitor of the inward current, the PcTX1 peptide, is described. Also provided are methods for screening compounds to inhibit the inward Na+ current, methods for screening for tumors expressing the inward Na current and methods for treating tumors expressing the inward Na current.

Abstract translation: 描述了在各种人类癌症中发现的本构内向Na +电流。 构成内向Na +电流在增加的细胞增殖，细胞迁移和体积调节中起作用。 内向电流至少部分由含AISC的Na +通道介导。 另外，描述了向内电流的抑制剂PcTX1肽。 还提供了筛选化合物以抑制内向性Na +电流的方法，筛选表达内向Na +电流的肿瘤的方法以及治疗表达内向Na +电流的肿瘤的方法。

公开(公告)号：WO2005012479A2

公开(公告)日：2005-02-10

申请号：PCT/US2004/020564

申请日：2004-06-25

Applicant: ABGENIX, INC ,  WEBER, Richard ,  FENG, Xiao ,  FOORD, Orit ,  GREEN, Larry ,  GUDAS, Jean ,  KEYT, Bruce ,  LIU, Ying ,  RATHANASWAMI, Palani ,  RAYA, Robert ,  YANG, Xiao, Dong ,  CORVALAN, Jose ,  FOLTZ, Ian ,  JIA, Xiao-Chi ,  KANG, Jaspal ,  KING, Chadwick, T. ,  KLAKAMP, Scott, L. ,  SU, Qiaojuan, Jane

Inventor： WEBER, Richard ,  FENG, Xiao ,  FOORD, Orit ,  GREEN, Larry ,  GUDAS, Jean ,  KEYT, Bruce ,  LIU, Ying ,  RATHANASWAMI, Palani ,  RAYA, Robert ,  YANG, Xiao, Dong ,  CORVALAN, Jose ,  FOLTZ, Ian ,  JIA, Xiao-Chi ,  KANG, Jaspal ,  KING, Chadwick, T. ,  KLAKAMP, Scott, L. ,  SU, Qiaojuan, Jane

IPC: C12N

CPC classification number: C07K16/30 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6897 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/77 ,  C07K2317/92 ,  Y10S435/81

Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

Abstract translation: 本发明涉及新型抗体，特别是针对表皮生长因子受体缺失突变体的抗体，特别是涉及III型缺失突变体EGFRvIII的抗体。 本发明还涉及针对表皮生长因子受体缺失突变体特别是EGFRvIII的人单克隆抗体。 还提供了此类抗体的诊断和治疗制剂及其免疫偶联物。

公开(公告)号：WO2005010151A2

公开(公告)日：2005-02-03

申请号：PCT/US2004020295

申请日：2004-06-25

Applicant: ABGENIX INC ,  WEBER RICHARD ,  FENG XIAO ,  FOORD ORIT ,  GREEN LARRY ,  GUDAS JEAN ,  KEYT BRUCE ,  LIU YING ,  RATHANASWAMI PALANI ,  RAYA ROBERT ,  YANG XIAO DONG ,  CORVALAN JOSE ,  FOLTZ IAN ,  JIA XIAO-CHI ,  KANG JASPAL ,  KING CHADWICK T ,  KLAKAMP SCOTT L ,  SU QIAOJUAN JANE

Inventor： WEBER RICHARD ,  FENG XIAO ,  FOORD ORIT ,  GREEN LARRY ,  GUDAS JEAN ,  KEYT BRUCE ,  LIU YING ,  RATHANASWAMI PALANI ,  RAYA ROBERT ,  YANG XIAO DONG ,  CORVALAN JOSE ,  FOLTZ IAN ,  JIA XIAO-CHI ,  KANG JASPAL ,  KING CHADWICK T ,  KLAKAMP SCOTT L ,  SU QIAOJUAN JANE

IPC: A61K39/395 ,  A61K47/48 ,  C07K16/22 ,  C07K16/28 ,  C07K17/00 ,  C12N20060101 ,  C12N5/06 ,  G01N33/53 ,  C12N

CPC classification number: C07K16/30 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6897 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/77 ,  C07K2317/92 ,  Y10S435/81

Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

Abstract translation: 本发明涉及新型抗体，特别是针对表皮生长因子受体缺失突变体的抗体，特别是涉及III型缺失突变体EGFRvIII的抗体。 本发明还涉及针对表皮生长因子受体缺失突变体特别是EGFRvIII的人单克隆抗体。 还提供了此类抗体的诊断和治疗制剂及其免疫缀合物。